Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 105 participants.

Also called NCT02409238

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02409238
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Singapore (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02409238. Randomized; no masking; primary purpose treatment. Start 2015-03-11 (actual); primary completion 2019-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study
Acronym
IRMCI
Condition
Mild Cognitive Impairment
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Metformin
Intervention (Behavioral)
Intensive Lifestyle Intervention
Intervention (Behavioral)
Standard LIfestyle Recommendation
Lead sponsor
SingHealth Polyclinics (class: other)
Collaborator
National University of Singapore (class: other)
Collaborator
Singapore General Hospital (class: other)
Collaborator
Changi General Hospital (class: other)
Collaborator
National University Hospital, Singapore (class: other)
Collaborator
Singapore Clinical Research Institute (class: other)
Collaborator
Agency for Science, Technology and Research (class: other)
Collaborator
Khoo Teck Puat Hospital (class: other)
Collaborator
Duke-NUS Graduate Medical School (class: other)

Record details

Record id
cardio:ct-nct02409238
Content hash
70e12db1498a20f24199b3ca42241d8cf78f91213be85bb77a723e1d3792c4b1